Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D esophageal cancer organoid chemosensitivity-guided adjuvant therapy
ChiCTR2500102227Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: 2-year recurrence-free survival rate and progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500102227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102227.